Get the Stockscreener App
49.56
4.42%
2.10
After Hours:
49.56
Vaxcyte Inc stock is traded at $49.56, with a volume of 1.74M.
It is up +4.42% in the last 24 hours and down -5.40% over the past month.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
See More
Previous Close:
$47.46
Open:
$47.71
24h Volume:
1.74M
Relative Volume:
1.23
Market Cap:
$7.16B
Revenue:
-
Net Income/Loss:
$-946.53M
P/E Ratio:
-7.1141
EPS:
-6.9664
Net Cash Flow:
$-814.94M
1W Performance:
+4.65%
1M Performance:
-5.40%
6M Performance:
+11.77%
1Y Performance:
+43.40%
1-Day Range:
$47.48
$50.05
1-Week Range:
$45.30
$50.05
52-Week Range:
$29.08
$65.00
Vaxcyte Inc Stock (PCVX) Company Profile
Name
Vaxcyte Inc
Sector
Industry
Phone
650-837-0111
Address
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
49.56 | 6.85B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-26 | Reiterated | Needham | Buy |
| Sep-12-25 | Initiated | Goldman | Neutral |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-24 | Initiated | Goldman | Buy |
| Dec-07-23 | Initiated | Mizuho | Buy |
| Apr-18-23 | Initiated | TD Cowen | Outperform |
| Jan-03-23 | Reiterated | Needham | Buy |
| Dec-15-22 | Initiated | Guggenheim | Buy |
| Nov-17-22 | Initiated | BTIG Research | Buy |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Jun-24-21 | Resumed | Jefferies | Buy |
| Jul-07-20 | Initiated | BofA Securities | Buy |
| Jul-07-20 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-07-20 | Initiated | Needham | Buy |
View All
Vaxcyte Inc Stock (PCVX) Latest News
PCVX: All proposals passed with strong support and no shareholder questions were raised - TradingView
PCVX: All board proposals passed with a strong quorum and no shareholder questions raised - TradingView
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
TD Asset Management Inc Cuts Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: A Biotech With A Promising 130% Upside Potential - DirectorsTalk Interviews
Norges Bank Invests $56.70 Million in Vaxcyte, Inc. $PCVX - MarketBeat
Average basic shares outstanding of Vaxcyte, Inc. – XETR:5VA - TradingView
Net current asset value per share of Vaxcyte, Inc. – XETR:5VA - TradingView
Total assets of Vaxcyte, Inc. – XETR:5VA - TradingView
EBIT per share of Vaxcyte, Inc. – XETR:5VA - TradingView
Vaxcyte, Inc. Balance Sheet – XETR:5VA - TradingView
Vaxcyte, Inc. Statistics – XETR:5VA - TradingView
Vaxcyte, Inc. Dividends – XETR:5VA - TradingView
Discipline and Rules-Based Execution in PCVX Response - Stock Traders Daily
Westfield Capital Management Co. LP Lowers Position in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX News | VAXCYTE INC (NASDAQ:PCVX) - ChartMill
Does Vaxcyte’s First-in-Human Group A Strep Trial Reshape The Bull Case For Vaxcyte (PCVX)? - simplywall.st
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC) - The Globe and Mail
Insider Sell Alert: Jim Wassil Sells Shares of Vaxcyte Inc (PCVX) - GuruFocus
Vaxcyte COO Jim Wassil sells $111k in PCVX stock - Investing.com UK
Vaxcyte COO Jim Wassil sells $111k in PCVX stock By Investing.com - Investing.com India
COO of Vaxcyte (NASDAQ: PCVX) sells 2,250 shares in pre-set plan - Stock Titan
Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $163 - Moomoo
Vaxcyte (PCVX) Takes First Steps in Human Vaccine Trials - GuruFocus
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults - Investing News Network
Vaxcyte Doses First Participant In Phase 1 Study Evaluating Vax-A1 For The Prevention Of Disease Caused By Group A Streptococcus In Healthy Adults - TradingView
Vaxcyte Begins Phase 1 Clinical Trial for Group A Streptococcus Vaccine Candidate VAX-A1 - geneonline.com
Vaxcyte doses first participant in group A strep vaccine trial - Investing.com
Vaxcyte doses first participant in group A strep vaccine trial By Investing.com - Investing.com Australia
Vaxcyte Doses First Participant in Phase 1 Study Evaluating - GlobeNewswire
Vaxcyte Inc stock (US92242T1016): Q1 2026 results and outlook ahead of next earnings date - AD HOC NEWS
PCVX insider sales disclosed: James Wassil sold 11,895 shares (PCVX) - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a Promising 112% Upside in the Biotech Sector - DirectorsTalk Interviews
Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments - Yahoo Finance
Vaxcyte Inc stock (US92242T1016): shares steady as Phase 3 pneumonia vaccine program advances - AD HOC NEWS
Assessing Vaxcyte (PCVX) Valuation After Mixed Short And Long Term Share Price Moves - simplywall.st
Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials - Yahoo Finance
Vaxcyte Inc. (PCVX) Slips 1.4% as Shares Test Key Support ZoneMA Cross Alert - The Legal Advocate
Top 3 Health Care Stocks You'll Regret Missing In MayVaxcyte (NASDAQ:PCVX), Universal Health Services - Benzinga
Behavioral Patterns of PCVX and Institutional Flows - Stock Traders Daily
Vaxcyte, Inc. (PCVX) Stock Analysis: Unpacking a 130% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Vaxcyte stock (US92242T1016): clinical-stage vaccine developer draws attention after recent capital - AD HOC NEWS
Vaxcyte (PCVX) slips 3.8% as investors digest recent ownership filings and cash-burn outlook - Quiver Quantitative
Why Vaxcyte (PCVX) Is Down 9.7% After Steeper Q1 Losses And Accelerated R&D Spending - simplywall.st
Pfizer Expands Pneumococcal Vaccine Push With New Programs - Benzinga
Vaxcyte, Inc. (PCVX) Stock Analysis: Biotech Innovator With Over 100% Upside Potential - DirectorsTalk Interviews
Vaxcyte Inc stock (US92242T1016): fresh data from pneumococcal vaccine program keeps biotech in focu - AD HOC NEWS
Vaxcyte stock (US92242T1016): Pneumococcal vaccine data keeps investors focused - AD HOC NEWS
RA Capital reports 12.97M shares in Vaxcyte (NASDAQ: PCVX) - Stock Titan
Janus Henderson (PCVX) discloses 16.6M shares, 11.5% ownership - Stock Titan
Jones Hill Capital LP's Vaxcyte Inc(PCVX) Holding History - GuruFocus
Vaxcyte Inc Stock (PCVX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):